CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
|Articles|June 27, 2012
Karen Ignagni, President and CEO, AHIP, Addresses How the Affordable Care Act Will Affect Consumers and Employers
Karen Ignagni, President and CEO, America's Health Insurance Plans (AHIP), states that higher costs and reductions in health plan options were consequences of states that did not link Affordable Care Act insurance market reforms and the individual mandate.
Advertisement
Karen Ignagni, President and CEO, America's Health Insurance Plans (AHIP), states that higher costs and reductions in health plan options were consequences of states that did not link Affordable Care Act insurance market reforms and the individual mandate.
By using Massachusetts as an example of analyzing the affect of subsidies before the mandate was passed, Ms. Ignagni says that there was an uptick in healthier and younger participants signing up, which is how the link between participation and market reform is intended to work. “Dividing, divorcing, and breaking that link really means that the market reforms that are in the legislation will not and cannot work as intended,” says Ms. Ignagni.
This video interview was taken on June 20, 2012, at the AHIP Institute 2012 in Salt Lake City, UT.
Advertisement
Related to this article
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.
Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
Advertisement
Advertisement
Trending on AJMC
1
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
2
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
3
FDA Approves First Heart Valve to Keep Pace With Children's Growth
4
Traditional Medicare OOP Cap Could Lower Costs, Raise Federal Spending
5